HLA-C and neoplasm: T cells specific for tumor-derived peptide antigens presented by MHC molecules have a critical role in controlling cancer progression5, and ex vivo engineering of T cells with MHC-restricted T cell receptors (TCR) specific for peptides derived from tumor antigens has the potential to generate large numbers of tumor-specific effector T cells from a patient5.